110
Participants
Start Date
April 28, 2021
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
SAR445088 (IV)
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
SAR445088 (SC)
Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
Columbia University Site Number : 8400005, New York
Investigational Site Number : 6880001, Belgrade
Investigational Site Number : 6880002, Belgrade
Investigational Site Number : 2500001, Marseille
Investigational Site Number : 3800003, Genova
Investigational Site Number : 6880003, Niš
Investigational Site Number : 3800005, Rozzano
Investigational Site Number : 3800001, Milan
Investigational Site Number : 2760002, Göttingen
Investigational Site Number : 2760001, Düsseldorf
Investigational Site Number : 2760003, Essen
Investigational Site Number : 7240003, Valencia
University of Minnesota Site Number : 8400006, Minneapolis
The University of Kansas Clinical Research Center Site Number : 8400003, Fairway
Investigational Site Number : 2760004, Tübingen
University of Southern California Site Number : 8400004, Los Angeles
Investigational Site Number : 2500004, Garches
University of California Irvine Site Number : 8400002, Orange
Investigational Site Number : 2500005, Le Kremlin-Bicêtre
Investigational Site Number : 1560001, Shanghai
Investigational Site Number : 1560002, Fuzhou
Investigational Site Number : 1560004, Wuhan
Investigational Site Number : 1240001, Gatineau
Investigational Site Number : 1240002, Québec
Investigational Site Number : 2500003, Bordeaux
Investigational Site Number : 2500002, Nice
Investigational Site Number : 3800002, Rome
Investigational Site Number : 5280001, Amsterdam
Investigational Site Number : 5280002, Utrecht
Investigational Site Number : 6160001, Lublin
Investigational Site Number : 7240002, Barcelona
Investigational Site Number : 7240001, Barcelona
Bioverativ, a Sanofi company
INDUSTRY